APPLICATION OF MASS SPECTROMETRY WITH PAPER SPRAY IONIZATION AND THE OPLS-DA CHEMOMETRIC METHOD FOR THE DIAGNOSIS OF PROSTATE CANCER BY ANALYSIS OF URINE SAMPLES. In this study, paper spray ionization mass spectrometry (PSI-MS) allied to orthogonal projections on the latent structure-discrimination analysis (OPLS-DA) was employed to differentiate urine samples from patients with prostate cancer and control individuals (without prostate cancer). The parameters of sensitivity, specificity, efficiency and Matthew’s correlation coefficient determined to analyze the efficiency and quality of the OPLS-DA model obtained a value equal to 1, which means, respectively, that the model has a good performance to correctly classify true positive samples and true negatives. These results showed 100% correct classification of the samples from the training and test set, demonstrating a high efficiency of the OPLS-DA model when classifying all samples considered as belonging to the class of interest (urine from control patient) into class 1 and all samples considered as belonging to the non-interest class (urine from patients with prostate cancer) in class 0. This efficiency resulting from the application of this model suggests that the PSI-MS combined to OPLS-DA is a promisor approach for a rapid diagnosis of prostate cancer, via chemical fingerprints of urine samples. OPLSDA OPLS DA SAMPLES study PSIMS PSI MS (PSI-MS structurediscrimination structure discrimination (OPLS-DA without cancer. . sensitivity specificity Matthews Matthew s means respectively negatives 100 set patient noninterest non 0 10

In this study, we aimed to investigate the anticancer activity of the extract, fractions, and isolated compounds of the flowers of Fridericia platyphylla, and to characterize the bioactive compounds. The chemical diversity of the extracts and fractions was investigated using liquid chromatography coupled with high resolution mass spectrometry (LC-HRMS). We were able to annotate 26 compounds from the classes of flavones, flavonols, flavanones, isoflavones, and cinnamic acid and its derivatives. The dichloromethane fraction showed greater cytotoxicity at a concentration of 100 µg mL−1. In addition, the inhibitory concentrations of the dichloromethane fraction were 22.14 and 30.9 µg mL−1 for MCF-7 and MDA-MB-231 cell lines, respectively, and were capable of inhibiting tumor cell migration. Brachydins A and C were isolated from the dichloromethane fraction and showed the greatest cytotoxicity. The results obtained from this study show the potential biological effect of F. platyphylla flowers as a possible antitumor pharmacological agent. extract LCHRMS. LCHRMS LC HRMS . (LC-HRMS) 2 flavones flavonols flavanones isoflavones derivatives 10 mL1 mL 1 addition 2214 22 14 22.1 309 30 9 30. mL− MCF7 MCF 7 MCF- MDAMB231 MDAMB MDA MB 231 MDA-MB-23 lines respectively migration F agent (LC-HRMS 221 22. 3 MDAMB23 23 MDA-MB-2 MDAMB2 MDA-MB- MDA-MB

Selenium-containing compounds exhibit diverse biological activities, such as antioxidative, anti-inflammatory, and cancer preventive effects. Using Caenorhabditis elegans as a model organism, we assessed the toxicity, neuroprotective, antioxidant properties, and impact on longevity of 11 selenoacetylenes. Their toxicity and bioactivities varied based on molecular structure. Selenoacetylenes with butyl substituents were toxic to Galleria mellonella larvae. The presence of but-3-in-2-ol radical increased antiprotozoal activity against Tetrahymena pyriformis. Compared to the positive control (Nimitz® EC), selenoacetylenes were less toxic to nematode worms and eggs. Selenoacetylenes significantly reduced amyloid beta (Aβ) paralysis in C. elegans CL4176 worms, increased longevity by 18 to 22%, along with improving survival after oxidative or thermal stress. Galantamine, showed inferior results. These findings enhance our understanding of selenoacetylenes on neuroprotection, antioxidant activity, and longevity in C. elegans. Future mammalian studies will further elucidate mechanisms and explore the potential therapeutic use of selenoacetylenes in treating Alzheimer’s disease and longevity. Seleniumcontaining Selenium containing activities antioxidative antiinflammatory, antiinflammatory anti inflammatory, inflammatory anti-inflammatory effects organism neuroprotective properties 1 structure larvae but3in2ol butinol but 3 2 ol pyriformis Nimitz® Nimitz (Nimitz EC, EC , EC) eggs Aβ (Aβ C CL CL417 22 22% stress Galantamine results neuroprotection Alzheimers Alzheimer s CL41 CL4

ABSTRACT Purpose: To describe the epidemiological and clinical profile of hospitalized patients with retinoblastoma in Brazil. Methods: Using data from the Hospital Cancer Registry of the Instituto Nacional de Câncer, patients with the morphological codes of retinoblastoma who were diagnosed between 2000 to 2018, aged 0–19 years, and followed up in registered hospitals (analytical cases) were selected. The relative and absolute frequencies of demographic, clinical, diagnostic, therapeutic, and outcome variables were described. Hospital performance indicators were calculated and compared between hospitals qualified and not qualified to treat pediatric oncology cases and between hospitals with different case volumes (<20, 20-75, >75 cases). Results: Of the 2,269 identified analytical cases from 86 institutions, 48% were from the Southeast, 54% were male, and 66% were aged <4 years. The proportion of missing data (NA) was too high for several variables. Approximately 84% of the patients were from the public health system, 40% had a positive family history, and 88% had unilateral involvement. The first treatment included surgery in 58.3% of the patients (NA=2), Approximately 36.6% of these patients achieved complete remission, 10.8% achieved partial remission, and 12.7% died (NA=59%). Hospital performance indicators were within the target in >90% of the patients. The median time between the first appointment and diagnosis (6 days, interquartile range [IQR] 1–14) was significantly lower and the median time to death was longer (343 days, IQR, 212-539) in high-volume hospitals (>75 cases) than in medium- and low-volume hospitals. Conclusions: Despite the high proportion of missing data, we found that the delay in diagnosis is due to prehospital factors. Additionally, there is a need for educational programs for healthcare professionals and families that emphasize early identification and referral to specialized centers. Future studies should focus on the impact of Hospital Cancer Registry data completeness on outcomes, causes of delay in diagnosis, regional inequalities, and barriers to accessing specialized services. Purpose Brazil Methods Câncer 200 2018 019 0 19 0–1 years selected demographic diagnostic therapeutic described <20, 20 (<20 2075, 2075 75, 75 20-75 >7 cases. . Results 2269 2 269 2,26 8 institutions 48 Southeast 54 male 66 4 < NA (NA 84 system 40 history 88 involvement 583 58 3 58.3 NA=2, NA2 NA=2 , (NA=2) 366 36 6 36.6 remission 108 10 10.8 127 12 7 12.7 NA=59%. NA59 NA=59% 59 (NA=59%) 90 >90 ( days IQR [IQR 1–14 114 1 14 343 (34 212539 212 539 212-539 highvolume volume (>7 medium lowvolume low Conclusions factors Additionally centers outcomes inequalities services 201 01 0– <20 (<2 207 20-7 > 226 26 2,2 5 58. NA= (NA=2 36. 10. 12. NA5 NA=59 (NA=59% 9 >9 1–1 11 34 (3 21253 21 53 212-53 (> <2 (< 20- 22 2, (NA= NA=5 (NA=59 1– 2125 212-5 (NA=5 212-

Coumarin derivatives possess diverse biological activities, encompassing antibacterial, antifungal, anticancer, antidiabetic, anti-inflammatory, and antioxidant effects. This study concentrates on the synthesis of two new coumarins: the first derived from rhizomes of Luvunga scandens and the second from 7-(diethylamino)-4-methyl-2H-chromen-2-one via bromination facilitated by NBS (N-bromosuccinimide) reagent. Their antibacterial and anticancer properties were evaluated in vitro, alongside in silico docking targeting the chromen-2-one group. Bromination of compound 1 yielded novel compound 2, while compound 4 was efficiently synthesized from 7-(diethylamino)-4-methyl-2H-chromen-2-one (3) using NBS. Testing on lung, breast, and liver cancer cell lines indicated that compound 2 effectively inhibited Staphylococcus aureus and Bacillus cereus at concentrations of 13.20 and 6.6 µM, respectively. It also demonstrated significant inhibition against MCF-7 breast cancer cells with a half-maximal inhibitory concentration (IC50) value of 50.37 ± 3.70 µM. Molecular docking revealed compound 2’s interaction with 2VF5 enzyme, elucidating its bacterial inhibition mechanism, with Gibbs energy and inhibition constant values of -7.42 kcal mol-1 and 3.62 µM, respectively. Additionally, compound 2 exhibited anticancer activity via alignment with topoisomerase 1 (3TOP): 1T8I, supported by molecular dynamics simulations illustrating strong ligand interactions. Analysis of pharmacophore kinetics highlighted the complex’s hydrophilic nature, indicating its potential therapeutic efficacy. activities antifungal antidiabetic antiinflammatory, antiinflammatory anti inflammatory, inflammatory anti-inflammatory effects coumarins 7diethylamino4methyl2Hchromen2one diethylaminomethylHchromenone 7 diethylamino methyl 2H chromen one H Nbromosuccinimide N bromosuccinimide (N-bromosuccinimide reagent vitro chromen2one chromenone group 3 (3 lung 1320 13 20 13.2 66 6 6. µM respectively MCF7 MCF MCF- halfmaximal half maximal IC50 IC (IC50 5037 50 37 50.3 370 70 3.7 2s s VF 2VF enzyme mechanism 7.42 742 42 -7.4 mol1 mol mol- 362 62 3.6 Additionally 3TOP TOP (3TOP) 1T8I TI T I interactions complexs complex nature efficacy Hchromen ( 132 13. IC5 (IC5 503 5 50. 3. 7.4 74 -7. 36 (3TOP (IC 7. -7 -

Considering the cytotoxic properties of Schiff base ligands, we re-synthesized a gold(III) complex with a tetradentate Schiff base ligand and investigated its cytotoxic effects using the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) method and sulforhodamine B staining method. The results showed that the gold(III) Schiff base complex can inhibit the growth of Chinese hamster ovary (CHO) cancer cell lines. However, unlike cisplatin, it does not induce cell death in NIH 3T3 normal cells. Real-time polymerase chain reaction (PCR) results revealed that the gold(III) Schiff base complex increased the Bak1/Bclx ratio in CHO cell line by 3.53-fold compared to the control, while cisplatin increased the anti-apoptotic Bclx gene by 31.8 times and the treatment resistance AKT1 gene by 430.8 times the control. However, cisplatin only activated the extrinsic pathway of apoptosis through the caspase-3 gene. The expression levels of TLR6 and TNF-α genes in normal cells showed that both the gold(III) Schiff base complex and cisplatin did not cause inflammation in NIH 3T3 cell lines. All the results indicate that the new complex could be a promising candidate to replace cisplatin. It has been shown that it induces apoptosis and prevents the development of resistance in cancer cells. Additionally, it does not cause inflammation in normal cells. ligands resynthesized re synthesized goldIII gold III gold(III 34,5dimethylthiazol2yl2,5diphenyltetrazolium 345dimethylthiazol2yl25diphenyltetrazolium dimethylthiazolyldiphenyltetrazolium 3 4,5 dimethylthiazol 2 yl 2,5 diphenyltetrazolium 4 5 bromide (CHO lines However T 3T Realtime Real time PCR (PCR Bak1Bclx BakBclx Bak1 Bak 3.53fold 353fold fold 3.53 53 control antiapoptotic anti apoptotic 318 31 8 31. AKT 4308 430 430. caspase3 caspase caspase- TLR TNFα TNF α Additionally 34 5dimethylthiazol2yl2 5diphenyltetrazolium 45 4, 25 2, 53fold 353 3.5 43 dimethylthiazolyl 5dimethylthiazol2yl 35 3.

A series of novel thieno[2,3-d]pyrimidine derivatives were designed, synthesized and evaluated for their biological ability. 2-Amino-4,7-dihydro-5H-thieno[2,3-d]pyrano-3-cyanonitrile was synthesized by Gewald reaction using pyranone as substrate, malonitrile and sulfur powder as raw materials and triethylamine as base at room temperature. Subsequent amination with N,N-dimethylformamide dimethyl acetal (DMF-DMA) gave N'-(3-cyano-4,7-dihydro-5H-thieno[2,3-c]pyran-2-yl)-N,N-dimethylmethanimidamide. In this article, the 23 thieno[2,3-d] pyrimidines were obtained by Dimroth rearrangement condensation with different anilines, 16 of them being new compounds. Meanwhile, all compounds were assessed for breast cancer MDA-MB-231 cell line bioactivity with paclitaxel (PTX) as the positive control, and all compounds in the series showed inhibitory effects on breast cancer cell MDA-MB-231. The IC50 of compound l against MDA-MB-231 is 27.6 μM, which is similar to that of PTX with an IC50 of 29.3 μM. This means that compound l exhibits comparable inhibitory activity to PTX in MDA-MB-231 cells and may be considered as a potential anti-MDA-MB-231 inhibitor. thieno2,3dpyrimidine thieno23dpyrimidine thienodpyrimidine thieno 2,3 d pyrimidine 2 3 designed ability 2Amino4,7dihydro5Hthieno2,3dpyrano3cyanonitrile 2Amino47dihydro5Hthieno23dpyrano3cyanonitrile AminodihydroHthienodpyranocyanonitrile Amino 4,7 dihydro 5H pyrano cyanonitrile 4 7 H substrate temperature N,Ndimethylformamide NNdimethylformamide N,N dimethylformamide N DMFDMA DMF DMA (DMF-DMA N3cyano4,7dihydro5Hthieno2,3cpyran2ylN,Ndimethylmethanimidamide. N3cyano47dihydro5Hthieno23cpyran2ylNNdimethylmethanimidamide NcyanodihydroHthienocpyranylNNdimethylmethanimidamide cyano c pyran yl dimethylmethanimidamide. dimethylmethanimidamide N'-(3-cyano-4,7-dihydro-5H-thieno[2,3-c]pyran-2-yl)-N,N-dimethylmethanimidamide article thieno2,3d thieno23d thienod thieno[2,3-d anilines 1 Meanwhile MDAMB231 MDAMB MDA MB 231 MDA-MB-23 (PTX control MDAMB231. 231. IC IC5 276 27 6 27. μM 293 29 29. antiMDAMB231 antiMDAMB anti anti-MDA-MB-23 inhibitor thieno2 3dpyrimidine dpyrimidine 2, 2Amino4 7dihydro5Hthieno2 3dpyrano3cyanonitrile Hthieno dpyrano 47 4, Ndimethylformamide NN N3cyano4 3cpyran2ylN Ndimethylmethanimidamide cpyran ylN N3cyano4,7dihydro5Hthieno2,3cpyran2ylN,Ndimethylmethanimidamide ylNNdimethylmethanimidamide 3d MDAMB23 MDA-MB-2 antiMDAMB23 anti-MDA-MB-2 2Amino dihydroHthieno 7dihydro5Hthieno dpyranocyanonitrile Ncyano N3cyano cpyranylN MDAMB2 MDA-MB- antiMDAMB2 anti-MDA-MB- MDA-MB anti-MDA-MB

ABSTRACT BACKGROUND: Radiation therapy (RT) is a standard treatment for non-metastatic breast cancer and is associated with acute and late toxicities. Intensity-modulated RT (IMRT) may decrease toxicity and is convenient for patients. OBJECTIVES: To assess the efficacy and safety of IMRT in women with early stage breast cancer. DESIGN AND SETTING: Systematic review study; Multi-institutional centers. METHODS: Seven databases were searched. Randomized controlled trials (RCT) comparing IMRT with any “non-IMRT” strategies were included. Primary outcomes were local control and acute toxicity. Cochrane Handbook was use to plan and conduct the review, and PRISMA 2020 was used to report results. RESULTS: Five RCT involving 2,556 women (n = 1,283 IMRT; n = 1,274 control arm) were included. Baseline characteristics were similar between trials and arms. Local relapse-free survival rates were not different (hazard-ratio [HR] 0.62; 95%confidence interval [CI] -0.38 to 1.62; P > 0.05); however, IMRT reduced the overall acute toxicity (RR 0.69, 95%CI 0.58 to 0.82; P < 0.00001) and acute moist desquamation (risk-ratio [RR] 0.71, 95%CI 0.60 to 0.82; P < 0.00001). Lymphedema and pneumonitis rates, and survival outcomes were not affected by IMRT. The 2-year telangiectasia rate was decreased with IMRT (RR 0.66, 95%CI 0.47 to 0.93; P = 0.02); however, edema, pain, pigmentation, or fibrosis remained unaffected. IMRT did not improve cosmesis. CONCLUSIONS: IMRT improved acute toxicity and lowered telangiectasia rates, without affecting oncological and aesthetic outcomes. SYSTEMATIC REVIEW REGISTRATION: This review was registered at Cochrane Database of Systematic Reviews 2013, Issue 3. Art. No.: CD010420. https://doi.org/10.1002/14651858.CD010420. BACKGROUND (RT nonmetastatic non metastatic toxicities Intensitymodulated Intensity modulated (IMRT patients OBJECTIVES SETTING study Multiinstitutional Multi institutional centers METHODS searched (RCT nonIMRT “non-IMRT included 202 results RESULTS 2556 2 556 2,55 1283 1 283 1,28 1274 274 1,27 arm arms relapsefree relapse free hazardratio hazard ratio HR [HR 0.62 062 0 62 95confidence confidence 95 CI [CI 0.38 038 38 -0.3 1.62 162 0.05 005 05 0.05) however RR 069 69 0.69 95CI 058 58 0.5 0.82 082 82 0.00001 000001 00001 riskratio risk [RR 071 71 0.71 060 60 0.6 0.00001. . 2year year 066 66 0.66 047 47 0.4 0.93 093 93 0.02 002 02 0.02) edema pain pigmentation unaffected cosmesis CONCLUSIONS REGISTRATION 2013 3 Art No. No CD010420 CD https//doi.org/10.1002/14651858.CD010420. httpsdoiorg10100214651858CD010420 httpsdoiorgCD https //doi.org/10.1002/14651858.CD010420. doi org 10 1002 14651858 https://doi.org/10.1002/14651858.CD010420 20 255 55 2,5 128 28 1,2 127 27 06 6 9 0.3 03 -0. 1.6 16 0.0 00 5 0. 0.8 08 8 0.0000 00000 0000 07 7 0.7 04 4 0.9 09 201 CD01042 https//doi.org/10.1002/14651858.CD010420 httpsdoiorg httpsdoiorg10100214651858CD01042 doiorg10100214651858CD010420 doiorgCD //doi.org/10.1002/14651858.CD010420 100 1465185 https://doi.org/10.1002/14651858.CD01042 25 2, 12 1, -0 1. 0.000 000 CD0104 https//doi.org/10.1002/14651858.CD01042 httpsdoiorg10100214651858CD0104 doiorg doiorg10100214651858CD01042 //doi.org/10.1002/14651858.CD01042 146518 https://doi.org/10.1002/14651858.CD0104 - 0.00 CD010 https//doi.org/10.1002/14651858.CD0104 httpsdoiorg10100214651858CD010 doiorg10100214651858CD0104 //doi.org/10.1002/14651858.CD0104 14651 https://doi.org/10.1002/14651858.CD010 CD01 https//doi.org/10.1002/14651858.CD010 httpsdoiorg10100214651858CD01 doiorg10100214651858CD010 //doi.org/10.1002/14651858.CD010 1465 https://doi.org/10.1002/14651858.CD01 CD0 https//doi.org/10.1002/14651858.CD01 httpsdoiorg10100214651858CD0 doiorg10100214651858CD01 //doi.org/10.1002/14651858.CD01 146 https://doi.org/10.1002/14651858.CD0 https//doi.org/10.1002/14651858.CD0 httpsdoiorg10100214651858CD doiorg10100214651858CD0 //doi.org/10.1002/14651858.CD0 14 https://doi.org/10.1002/14651858.CD https//doi.org/10.1002/14651858.CD doiorg10100214651858CD //doi.org/10.1002/14651858.CD

ABSTRACT Purpose: We reported, as a referral center in prostate cancer, our perspectives and experience performing Telesurgery using robotic surgery and 5G network. Material and methods: We described and illustrated the Telesurgery applications and outcomes to treat a patient with prostate cancer located 1300 kilometers away from the surgeon (Beijing-Harbin) in China. We used the Edge Medical Robot (MP1000) in November 2023 in a 71-year-old patient with Gleason 6 (ISUP 1) in 8 cores from 13, PSA of 14 ng/dL, and clinical stage cT2a. MRI described a PIRADS 5 nodule on the left peripheral zone at the base, and 20gr prostate. We described details about the connection between centers, perioperative outcomes, and our perspectives as a referral center in prostate cancer. Results: We had no delays, or problems with network connection between the centers. The procedure was performed in 60 minutes, with no intra- or postoperative complications. Estimated blood loss was 100 mL. The patient was ambulating soon after anesthesia recovery. Final pathology described a Gleason 6 (ISUP 1) involving the left base and left seminal vesicle, negative surgical margins, and no lymph node involvement (pT3bN0). The patient was continent soon after catheter removal (7 days). Conclusion: As technological progress introduced novel robotic platforms and high-speed networks, the concept of Telesurgery became a tangible reality while 5G technology solved latency and transmission concerns. However, with these advancements, ethical considerations and regulatory frameworks should underline the importance of transparency and patient safety with responsible innovation in the field. Purpose reported G methods 130 BeijingHarbin Beijing Harbin (Beijing-Harbin China MP1000 MP (MP1000 202 71yearold yearold 71 year old ISUP 1 13 ngdL ng dL ng/dL cT2a cTa cT gr centers Results delays minutes intra complications 10 mL recovery vesicle margins pT3bN0. pT3bN0 pTbN . pT bN (pT3bN0) 7 ( days. days days) Conclusion highspeed high speed networks concerns However advancements field MP100 (MP100 20 pT3bN (pT3bN0 MP10 (MP10 2 (pT3bN MP1 (MP1 (MP

ABSTRACT Introduction: Robotic Radical Prostatectomy using the Da-Vinci Single-Port (SP) robot can provide comparable functional and oncological outcomes with potential advantages pertaining to peri-operative morbidity, especially in patients with an extensive history of prior abdominal surgeries (1, 2). Materials and Methods: Our case is a 74-year-old male with a history of diabetes, cardiac bypass, hypertension, and hyperlipidemia, presenting with a PSA of 7.2. His MRI showed a PIRADS-5 lesion in the left apex and mid-gland peripheral zone, and he was diagnosed with unfavorable intermediate-risk prostate cancer after MRI guided fusion biopsy. His BMI was 31, and past surgical history was pertinent for two exploratory laparotomies due to gunshot wounds and a colostomy creation followed by reversal. The standardized steps of robotic radical prostatectomy were carried out using SP robotic platform performed by author SH (3, 4). Results: Total operative time and estimated blood loss were 210 minutes and 150mL respectively. The patient was discharged on postoperative day one and final pathology showed adenocarcinoma of the prostate Gleason score 4+3=7, pT2NxR0 and negative surgical margins. The patient was continent four weeks after surgery and the PSA continues to be undetectable after three months. Conclusion: Transvesical Radical prostatectomy using the single port platform provides acceptable oncological and functional outcomes and quicker recovery given decreased risk of ileus and peritoneal irritation. Given that the abdominal cavity is not violated, the risk of bowel or vascular injury is mitigated, especially in patients with a hostile abdomen. Introduction DaVinci Da Vinci SinglePort Single Port (SP perioperative peri morbidity 1, 1 (1 2. 2 . 2) Methods 74yearold yearold 74 year old diabetes bypass hypertension hyperlipidemia 72 7 7.2 PIRADS5 PIRADS 5 PIRADS- midgland mid gland zone intermediaterisk intermediate biopsy 31 reversal 3, 3 (3 4. 4 4) Results 21 mL respectively 437 4+3=7 pTNxR pT NxR pT2NxR margins months Conclusion irritation violated mitigated abdomen ( 7. 43 4+3= 4+3 4+

ABSTRACT Objectives: To evaluate the safety and effectiveness of robot-assisted radical cystectomy (RARC), laparoscopic radical cystectomy (LRC), and open radical cystectomy (ORC) in bladder cancer. Methods: A literature search for network meta-analysis was conducted using international databases up to February 29, 2024. Outcomes of interest included baseline characteristics, perioperative outcomes and oncological outcomes. Results: Forty articles were finally selected for inclusion in the network meta-analysis. Both LRC and RARC were associated with longer operative time, smaller amount of estimated blood loss, lower transfusion rate, shorter time to regular diet, fewer incidences of complications, and fewer positive surgical margin compared to ORC. LRC had a shorter time to flatus than ORC, while no difference between RARC and ORC was observed. Considering lymph node yield, there were no differences among LRC, RARC and ORC. In addition, there were statistically significant lower transfusion rates (OR=-0.15, 95% CI=-0.47 to 0.17), fewer overall complication rates (OR=-0.39, 95% CI=-0.79 to 0.00), fewer minor complication rates (OR=-0.23, 95% CI=-0.48 to 0.02), fewer major complication rates (OR=-0.23, 95% CI=-0.68 to 0.21), fewer positive surgical margin rates (OR=0.22, 95% CI=-0.27 to 0.68) in RARC group compared with LRC group. Conclusion: LRC and RARC could be considered as a feasible and safe alternative to ORC for bladder cancer. Notably, compared with LRC, RARC may benefit from significantly lower transfusion rates, fewer complications and lower positive surgical margin rates. These data thus showed that RARC might improve the management of patients with muscle invasive or high-risk non-muscle invasive bladder cancer. Objectives robotassisted robot assisted RARC, , (RARC) (LRC) (ORC cancer Methods metaanalysis meta analysis 29 2024 characteristics Results metaanalysis. analysis. loss rate diet observed yield addition OR=0.15, OR015 OR OR= 0.15, 0 15 (OR=-0.15 95 CI=0.47 CI047 CI CI= 0.47 47 CI=-0.4 0.17, 017 0.17 17 0.17) OR=0.39, OR039 0.39, 39 (OR=-0.39 CI=0.79 CI079 0.79 79 CI=-0.7 0.00, 000 0.00 00 0.00) OR=0.23, OR023 0.23, 23 (OR=-0.23 CI=0.48 CI048 0.48 48 0.02, 002 0.02 02 0.02) CI=0.68 CI068 0.68 68 CI=-0.6 0.21, 021 0.21 21 0.21) OR=0.22, OR022 22 (OR=0.22 CI=0.27 CI027 0.27 27 CI=-0.2 068 Conclusion Notably highrisk high risk nonmuscle non (RARC (LRC 2 202 OR=0.15 OR01 015 0.15 1 (OR=-0.1 9 CI=0.4 CI04 047 0.4 4 CI=-0. 01 0.1 OR=0.39 OR03 039 0.39 3 (OR=-0.3 CI=0.7 CI07 079 0.7 7 0.0 OR=0.23 OR02 023 0.23 (OR=-0.2 048 CI=0.6 CI06 0.6 6 0.2 OR=0.22 (OR=0.2 CI=0.2 CI02 027 06 20 OR=0.1 OR0 (OR=-0. CI=0. CI0 04 0. CI=-0 OR=0.3 03 0.3 07 OR=0.2 (OR=0. OR=0. (OR=-0 CI=0 CI=- (OR=0 OR=0 (OR=- (OR= (OR

Abstract Objective To assess the outcome of patients with cancer-related sepsis requiring continuous renal replacement therapy (CRRT) in a single-center pediatric intensive care unit (PICU). Method Children with sepsis who necessitate CRRT from January 2017 to December 2021 were enrolled. The patients with leukemia/lymphoma or solid tumors were defined as underlying cancer. Multivariate logistic regression analysis was performed to identify the death risk factors in patients with cancer-related sepsis. Results A total of 146 patients were qualified for inclusion. Forty-six (31.5%) patients with cancer-related sepsis and 100 (68.5%) non-cancer-related sepsis. The overall PICU mortality was 28.1% (41/146), and mortality was significantly higher in cancer-related sepsis patients compared with non-cancer patients (41.3% vs. 22.0%, p = 0.016). Need mechanical ventilation, p-SOFA, acute liver failure, higher fluid overload at CRRT initiation, hypoalbuminemia, and high inotropic support were associated with PICU mortality in cancer-related sepsis patients. Moreover, levels of IL-6, total bilirubin, creatinine, blood urea nitrogen, and international normalized ratio were significantly higher in non-survivors than survivors. In multivariate logistic regression analysis, pediatric sequential organ failure assessment (p-SOFA) score (OR:1.805 [95%CI: 1.047-3.113]) and serum albumin level (OR: 0.758 [95%CI: 0.581 -0.988]) were death risk factors in cancer-related sepsis receiving CRRT, and the AUC of combined index of p-SOFA and albumin was 0.852 (95% CI: 0.730-0.974). Conclusion The overall PICU mortality is high in cancer-related sepsis necessitating CRRT. Higher p-SOFA and lower albumin were independent risk factors for PICU mortality. cancerrelated cancer related (CRRT singlecenter single center PICU. . (PICU) 201 202 enrolled leukemialymphoma leukemia lymphoma 14 inclusion Fortysix Forty six 31.5% 315 31 5 (31.5% 10 68.5% 685 68 (68.5% noncancerrelated non 281 28 1 28.1 41/146, 41146 41/146 , 41 (41/146) noncancer 41.3% 413 3 (41.3 vs 220 22 0 22.0% 0.016. 0016 0.016 016 0.016) ventilation pSOFA, pSOFA SOFA, SOFA initiation hypoalbuminemia Moreover IL6, IL6 IL 6, 6 IL-6 bilirubin creatinine nitrogen nonsurvivors survivors (p-SOFA OR1.805 OR1805 OR 1.805 805 (OR:1.80 95%CI 95CI CI 95 [95%CI 1.0473.113 10473113 1.047 3.113 047 113 1.047-3.113] (OR 0758 758 0.75 0581 581 0.58 0.988 0988 988 -0.988] 0852 852 0.85 95% (95 0.7300.974. 07300974 0.730 0.974 730 974 0.730-0.974) (PICU 20 31.5 (31.5 68.5 (68.5 2 28. 4114 41/14 4 (41/146 41.3 (41. 22.0 001 0.01 01 IL- OR1 OR1.80 OR180 1805 1.80 80 (OR:1.8 9 0473 1.0473.11 1047311 1047 1.04 3113 3.11 04 11 1.047-3.113 075 75 0.7 058 58 0.5 0.98 098 98 -0.988 085 85 0.8 (9 7300 0.7300.974 0730097 0730 0.73 0974 0.97 73 97 0.730-0.974 31. (31. 68. (68. 411 41/1 (41/14 41. (41 22. 00 0.0 OR1.8 OR18 180 1.8 8 (OR:1. 1.0473.1 104731 104 1.0 311 3.1 1.047-3.11 07 7 0. 05 0.9 09 -0.98 08 ( 0.7300.97 073009 073 097 0.730-0.97 (31 (68 41/ (41/1 (4 OR1. 18 1. (OR:1 1.0473. 10473 3. 1.047-3.1 -0.9 0.7300.9 07300 0.730-0.9 (3 (6 (41/ 1.0473 1.047-3. -0. 0.7300. 0.730-0. 1.047-3 -0 0.7300 0.730-0 1.047- - 0.730-

SUMMARY OBJECTIVE: The objective of this study was to analyze the genetic alterations of tumors within the scope of the homologous recombination deficiency gene panel in patients diagnosed with synchronous endometrial ovarian cancer who have been followed for over 5 years using next-generation sequencing. METHODS: DNA was isolated from the patient’s formalin-fixed, paraffin-embedded tissue blocks. Next-generation sequencing was performed using the Illumina capture-based sequencing method. Samples were sequenced using the Sophia HR Solution DNA Kit. RESULTS: Seven patients were included in this study. The ratios of likely pathogenic (LP)/pathogenic (P) somatic mutations in ATM (serine/threonine kinase or Ataxia-telangiectasia mutated gene), BRCA2 (breast cancer type 2 susceptibility gene), BARD1 (BRCA1 associated RING domain 1), TP53 (tumor protein p53), BIRP1 (BRCA1-interacting helicase 1 gene), PALB2 (partner and localizer of BRCA2), and CHECK2 were 21 (48.8%), 8 (18.6%), 5 (11.6%), 3 (6.9%), 2 (4.6%), 2 (4.6%), and 2 (4.6%), respectively, in endometrium, and the ratios of somatic mutations in ATM, BRCA2, TP53, BARD1, RAD54L (DNA repair/recombination protein like), BIRP1, and RAD51D (RAD51 recombinase paralog D) were 24 (60%), 6 (15%), 5 (12.5%), 2 (5%), 2 (5%), 1 (2.5%), and 1 (2.5%), respectively, in ovary. In endometrioid-synchronous endometrial ovarian cancer cases, P/LP mutations were observed in ATM and CHECK2 genes in endometrium and ATM, BRCA2, and TP53 genes in ovary. In two non-endometrioid-synchronous endometrial ovarian cancer cases, CHEK2 (checkpoint kinase 2) mutations were observed in endometrium and ATM and TP53 mutations in ovary, whereas in one case, P/LP mutations in ATM and TP53 genes were common in both tissues. CONCLUSION: Pathogenic variations confirming the diagnosis of synchronous endometrial ovarian cancer with genetic alterations were identified in all but one case. ATM gene mutation emerged as the most common alteration and has a potential association with a favorable prognosis. OBJECTIVE nextgeneration next generation METHODS patient s formalinfixed, formalinfixed formalin fixed, fixed formalin-fixed paraffinembedded paraffin embedded blocks Nextgeneration Next capturebased capture based method Kit RESULTS LP/pathogenic LPpathogenic LP /pathogenic P (P serine/threonine serinethreonine serine threonine Ataxiatelangiectasia Ataxia telangiectasia gene, , gene) BRCA breast BARD BRCA1 (BRCA 1, 1) TP TP5 tumor p53, p53 p p53) BIRP BRCA1interacting BRCAinteracting interacting PALB partner BRCA2) CHECK 48.8%, 488 48.8% 48 (48.8%) 18.6%, 186 18.6% 18 (18.6%) 11.6%, 116 11.6% 11 (11.6%) 6.9%, 69 6.9% 9 (6.9%) 4.6%, 46 4.6% 4 (4.6%) respectively RADL RAD L repairrecombination repair like, like like) RADD D RAD51 (RAD5 60%, 60 60% (60%) 15%, 15 15% (15%) 12.5%, 125 12.5% 12 (12.5%) 5%, 5% (5%) 2.5%, 25 2.5% (2.5%) ovary endometrioidsynchronous endometrioid cases PLP nonendometrioidsynchronous non CHEK checkpoint case tissues CONCLUSION prognosis p5 48.8 (48.8% 18.6 (18.6% 11.6 (11.6% 6.9 (6.9% 4.6 (4.6% RAD5 (RAD (60% (15% 12.5 (12.5% (5% 2.5 (2.5% 48. (48.8 18. (18.6 11. (11.6 6. (6.9 4. (4.6 (60 (15 12. (12.5 (5 2. (2.5 (48. (18. (11. (6. (4. (6 (1 (12. ( (2. (48 (18 (11 (4 (12 (2